Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-Month results of a Korean RVO study

Japanese Journal of Ophthalmology

Volumn 58, Issue 2, 2014, Pages 146-154

  Yoon, Young Hee ^a   Kim, Ha Kyoung ^b   Yoon, Hee Seong ^c   Kang, Se Woong ^d   Kim, June Gone ^a   Park, Kyu Hyung ^e   Jo, Young Joon ^f   Lee, Joo Yong ^a   Lee, Dong Hoon ^a  

^a University of Ulsan   (South Korea)

^b Hallym University   (South Korea)

^c St Mary's Eye Hospital   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

Author keywords

Duration of symptom; Early treatment; Korean patients; Macular edema; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE STUDY; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DISEASE DURATION; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; SECONDARY PREVENTION; TIME FACTORS; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84896489165     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-014-0305-9     Document Type: Article

References (16)

1. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363:2135-44.
2. Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92:1316-9.
3. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1094-101):e5.
4. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1113-23):e15.
5. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453-60.
6. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1102-1112):e1.
7. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1124-33):e1.
8. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-28.
9. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-14.
10. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology. 2012;119:1190-8.
11. Lee JY, Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, et al. Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO study group. J Korean Med Sci. 2013;28:136-44.
12. Kiernan DF, Hariprasad SM. Normative databases in SD-OCT: a status report. In: Retinal physician. http://www.retinalphysician.com/articleviewer. aspx?articleID=104438. Accessed 1 Apr 2012.
13. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56:165-74.
14. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, et al. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. Ophthalmology. 2011;118:345-52.
15. Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A. Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol. 2012;56:159-64.
16. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802-9.